CRO services within obesity

Accelerate your drug development by exploring clinical endpoints in our
validated obese mouse models 

Ob/ob mouse model

  • Hyperphagia-driven overt obesity
  • Marked insulin resistance and glucose intolerance
  • Mild hyperglycemia
  • Intact leptin receptor signalling
  • Treatment efficacy across a wide range of anti-obesity and anti-diabetic drug classes

Gubra 3D Experience

To enable fast and efficient data mining of quantitative 3D imaging data, Gubra has developed a web-based 3D imaging data viewer (Gubra 3D Experience, G3DE). This resource provides researchers with a platform for exploring Gubra’s published 3D imaging data in further detail.

G3DE is particularly relevant in preclinical drug development for obesity. Click here to explore individual brain regions of interest, display quantitative c-Fos data and filter for regions with statistically significant response to drug treatment.

Download paper: Whole-brain activation signatures of weight-lowering drugs. Article and front cover of Molecular Metabolism (Vol 47 – May 2021). 

Whole-brain imaging of drug distribution

Anti-obesity drugs may cross the blood-brain barrier to engage with appetite-regulating regions. Gubra uses 3D imaging to determine whole-brain distribution of fluorescently tagged therapeutic peptides and antibodies.

Download poster: Whole-brain distributional differences of lipidated Exendin-4 peptides

Download flyer: Whole-organ drug distribution

View video in separate window

 

Types of studies

Acute efficacy studies

In an acute efficacy study we offer e.g.

 

  • OGTT/IPGTT/IVGTT and ITT in rats and mice
  • Automatized food intake testing
  • Conditioned taste aversion testing
  • In vitro biology

Chronic efficacy studies

 In a chronic efficacy study we offer e.g.

 

  • Body weight, food intake, food preference
  • Chronic efficacy testing (7 days to 12+ weeks)
  • EchoMRI determination of body fat and tissue fat (e.g. liver)
  • Ex vivo assays (TG, Chol, FFAs, Hormones: Leptin, ghrelin, glucagon, insulin, GLP-1, GIP, PYY3-36 etc.)

Mode of action studies

In a mode of action study we offer e.g.

 

  • EchoMRI
  • Energy expenditure and metabolic cages
  • Conditioned taste aversion and pica behavior
  • Selective vagal deafferentation (SDA) and area postrema ablation
  • Bariatric surgery
  • Blood pressure
  • c-Fos – a marker of neuronal activation
  • CNS drug distribution

Gubra in vivo study approach in obesity

We conduct preclinical obesity studies in the vast majority of all commercially available rodent models. 

Years of scientific and technical CRO expertise, combined with our constant animal availability and readiness, translate into speed and high scientific standards. We provide solid data and scientific guidance which you can use as the foundation for business decisions to move your projects forward.

 

Related Links:

Main offerings

 

  • DIO models and the majority of commercially available models.
  • Acute or chronic anorectic properties assessed in real-time food/water/activity monitoring system.
  • Monitoring of food preference, taste aversion and pica behavior.
  • Site-specific compound administration, e.g. intrathecal, intracerebroventricular or local injections into specific brain nuclei.
  • Total body fat measurements using our EchoMRI scanner.
  • Tissue fat measurements using small sample EchoMRI scanner.
  • Energy expenditure testing using indirect calorimetry.
  • In vivo lipogenesis.
  • Selective vagal deafferentiation and other MoA validations.
  • RNA sequencing and bioinformatics.

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Michael Feigh

Director

mfe@gubra.dk
+45 2382 9493